Matthias Ritgen

5PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 27, 2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

|Dec 08, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Othman Al-Sawaf, Janina Stumpf, Can Zhang

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Barbara Eichhorst, Carsten U Niemann, Arnon P Kater

|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

Moritz Fürstenau, Jonathan Weiss, Adam Giza

Pageof 1

Frequent Collaborators

3 joint publications

Moritz Fürstenau

2 joint publications

Othman Al-Sawaf

1 joint publications

Sandra Robrecht

1 joint publications

Anna-Maria Fink